Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species
We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 50(2006), 6 vom: 24. Juni, Seite 2244-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gavin, Patrick J [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 01.08.2006 Date Revised 01.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM163026858 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM163026858 | ||
| 003 | DE-627 | ||
| 005 | 20231223095459.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0544.xml |
| 035 | |a (DE-627)NLM163026858 | ||
| 035 | |a (NLM)16723596 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gavin, Patrick J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2006 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a beta-Lactamase Inhibitors |2 NLM | |
| 650 | 7 | |a Piperacillin, Tazobactam Drug Combination |2 NLM | |
| 650 | 7 | |a 157044-21-8 |2 NLM | |
| 650 | 7 | |a Penicillanic Acid |2 NLM | |
| 650 | 7 | |a 87-53-6 |2 NLM | |
| 650 | 7 | |a Piperacillin |2 NLM | |
| 650 | 7 | |a X00B0D5O0E |2 NLM | |
| 700 | 1 | |a Suseno, Mira T |e verfasserin |4 aut | |
| 700 | 1 | |a Thomson, Richard B |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Gaydos, J Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Pierson, Carl L |e verfasserin |4 aut | |
| 700 | 1 | |a Halstead, Diane C |e verfasserin |4 aut | |
| 700 | 1 | |a Aslanzadeh, Jaber |e verfasserin |4 aut | |
| 700 | 1 | |a Brecher, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Rotstein, Coleman |e verfasserin |4 aut | |
| 700 | 1 | |a Brossette, Stephen E |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, Lance R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 50(2006), 6 vom: 24. Juni, Seite 2244-7 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2006 |g number:6 |g day:24 |g month:06 |g pages:2244-7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2006 |e 6 |b 24 |c 06 |h 2244-7 | ||